RxDoctor Payments Data

Frank Papik, MD

Pulmonary Disease · Seneca, SCNPI 1235633157

Payments from drug & device makers

$598in general payments, 2019–2025

Across 27 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$173
  • AstraZeneca$147
  • Grifols USA, LLC$70
  • United Therapeutics Corporation$47
  • Regeneron Healthcare Solutions, Inc.$36
  • Insmed, Inc.$34
  • plus $91 from 4 others

What the payments were for

  • Food & beverage$56494%
  • Education$346%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$598 in reported general payments places this provider in the 25th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$30,317
Medicare patients
123
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor12$103,473
Dupixent PenDupilumab15$55,980
Spiriva RespimatTiotropium Bromide28$23,724
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$20,737
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,980
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$12,083
DuleraMometasone/Formoterol17$6,072
SymbicortBudesonide/Formoterol Fumarate16$4,380
Albuterol Sulfate HfaAlbuterol Sulfate42$1,205
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,065
Ventolin HfaAlbuterol Sulfate14$819
Montelukast Sodium32$347
Azelastine Hcl15$280
Fluticasone Propionate16$188
Prednisone11$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCProlastin C$70$103,47312 claims
AstraZenecaBreztri Aerosphere, Symbicort$147$25,11739 claims
GSKTrelegy Ellipta$173$16,98024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in Seneca

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →